44 related articles for article (PubMed ID: 38752476)
1. One versus two sets of busulfan therapeutic drug monitoring in myeloablative allogeneic hematopoietic cell transplant.
Chippendale L; Freyer CW; Carulli A; Babushok DV; Frey NV; Gill SI; Hexner EO; Luger SM; Martin ME; Porter DL; Stadtmauer EA; Loren AW
J Oncol Pharm Pract; 2024 Jul; 30(5):802-810. PubMed ID: 37603585
[TBL] [Abstract][Full Text] [Related]
2. Second allogeneic haematopoietic stem cell transplant conditioned with treosulfan and fludarabine is associated with encouraging overall survival and transplant related mortality in late relapse of myeloid malignancies.
Avenoso D; Lionel S; Maraj A
Bone Marrow Transplant; 2024 Jun; ():. PubMed ID: 38871962
[No Abstract] [Full Text] [Related]
3. Treosulfan is a safe and effective alternative to busulfan for conditioning in adult allogeneic HSCT patients: Data from a single center.
Uzay A; Gündoğdu Y; Koşan B; Yetiş T; Kartı SS
Cancer Med; 2024 May; 13(10):e7292. PubMed ID: 38752476
[TBL] [Abstract][Full Text] [Related]
4. Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Nagler A; Labopin M; Beelen D; Ciceri F; Volin L; Shimoni A; Foá R; Milpied N; Peccatori J; Polge E; Mailhol A; Mohty M; Savani BN
Cancer; 2017 Jul; 123(14):2671-2679. PubMed ID: 28329410
[TBL] [Abstract][Full Text] [Related]
5. A retrospective study of treosulfan versus busulfan-based conditioning in pediatric patients.
Olivas-Mazón R; Bueno D; Sisinni L; Mozo Y; Casado-Abad G; Martínez AP
Eur J Haematol; 2022 Nov; 109(5):474-482. PubMed ID: 35810360
[TBL] [Abstract][Full Text] [Related]
6. Treosulfan-thiotepa-fludarabine-based conditioning regimen for allogeneic transplantation in patients with thalassemia major: a single-center experience from north India.
Choudhary D; Sharma SK; Gupta N; Kharya G; Pavecha P; Handoo A; Setia R; Katewa S
Biol Blood Marrow Transplant; 2013 Mar; 19(3):492-5. PubMed ID: 23160007
[TBL] [Abstract][Full Text] [Related]
7. Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial.
Beelen DW; Trenschel R; Stelljes M; Groth C; Masszi T; Reményi P; Wagner-Drouet EM; Hauptrock B; Dreger P; Luft T; Bethge W; Vogel W; Ciceri F; Peccatori J; Stölzel F; Schetelig J; Junghanß C; Grosse-Thie C; Michallet M; Labussiere-Wallet H; Schaefer-Eckart K; Dressler S; Grigoleit GU; Mielke S; Scheid C; Holtick U; Patriarca F; Medeot M; Rambaldi A; Micò MC; Niederwieser D; Franke GN; Hilgendorf I; Winkelmann NR; Russo D; Socié G; Peffault de Latour R; Holler E; Wolff D; Glass B; Casper J; Wulf G; Menzel H; Basara N; Bieniaszewska M; Stuhler G; Verbeek M; Grass S; Iori AP; Finke J; Benedetti F; Pichlmeier U; Hemmelmann C; Tribanek M; Klein A; Mylius HA; Baumgart J; Dzierzak-Mietla M; Markiewicz M
Lancet Haematol; 2020 Jan; 7(1):e28-e39. PubMed ID: 31606445
[TBL] [Abstract][Full Text] [Related]
8. Treosulfan and fludarabine low-toxicity conditioning for allogeneic haematopoietic stem cell transplantation in chronic myeloid leukaemia.
Holowiecki J; Giebel S; Wojnar J; Krawczyk-Kulis M; Markiewicz M; Holowiecka-Goral A; Freund M; Casper J
Br J Haematol; 2008 Jun; 142(2):284-92. PubMed ID: 18492101
[TBL] [Abstract][Full Text] [Related]
9. The Correlation Between Busulfan Exposure and Clinical Outcomes in Chinese Pediatric Patients: A Population Pharmacokinetic Study.
Du X; Huang C; Xue L; Jiao Z; Zhu M; Li J; Lu J; Xiao P; Zhou X; Mao C; Zhu Z; Dong J; Liu X; Chen Z; Zhang S; Ding Y; Hu S; Miao L
Front Pharmacol; 2022; 13():905879. PubMed ID: 35784763
[No Abstract] [Full Text] [Related]
10. Treosulfan compared with reduced-intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Final analysis of a prospective randomized trial.
Beelen DW; Stelljes M; Reményi P; Wagner-Drouet EM; Dreger P; Bethge W; Ciceri F; Stölzel F; Junghanß C; Labussiere-Wallet H; Schaefer-Eckart K; Grigoleit GU; Scheid C; Patriarca F; Rambaldi A; Niederwieser D; Hilgendorf I; Russo D; Socié G; Holler E; Glass B; Casper J; Wulf G; Basara N; Bieniaszewska M; Stuhler G; Verbeek M; La Rocca U; Finke J; Benedetti F; Pichlmeier U; Klein A; Baumgart J; Markiewicz M
Am J Hematol; 2022 Aug; 97(8):1023-1034. PubMed ID: 35617104
[TBL] [Abstract][Full Text] [Related]
11. Impact of busulfan pharmacokinetics on outcome in adult patients receiving an allogeneic hematopoietic cell transplantation.
Seydoux C; Battegay R; Halter J; Heim D; Rentsch KM; Passweg JR; Medinger M
Bone Marrow Transplant; 2022 Jun; 57(6):903-910. PubMed ID: 35361896
[TBL] [Abstract][Full Text] [Related]
12. GITMO Registry Study on Allogeneic Transplantation in Patients Aged ≥60 Years from 2000 to 2017: Improvements and Criticisms.
Malagola M; Polverelli N; Rubini V; Martino M; Patriarca F; Bruno B; Giaccone L; Grillo G; Bramanti S; Bernasconi P; De Gobbi M; Natale A; Terruzzi E; Olivieri A; Chiusolo P; Carella AM; Casini M; Nozzoli C; Mazza P; Bassi S; Onida F; Vacca A; Falcioni S; Luppi M; Iori AP; Pavone V; Skert C; Carluccio P; Borghero C; Proia A; Selleri C; Sacchi N; Mammoliti S; Oldani E; Ciceri F; Russo D; Bonifazi F
Transplant Cell Ther; 2022 Feb; 28(2):96.e1-96.e11. PubMed ID: 34818581
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Outcomes of Treosulfan- vs. Busulfan-Based Conditioning Regimen for Patients With Myelodysplastic Syndrome and Acute Myeloid Leukemia Before Hematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis.
Zhu S; Liu G; Liu J; Chen Q; Wang Z
Front Oncol; 2020; 10():591363. PubMed ID: 33425740
[TBL] [Abstract][Full Text] [Related]
14. Local immune cell infiltration in cutaneous acute graft versus host disease.
Sennett R; Jama BM; Hinds B; Tzachanis D; Morris GP; Marsch AF
Int J Womens Dermatol; 2020 Sep; 6(4):311-317. PubMed ID: 33015293
[TBL] [Abstract][Full Text] [Related]
15. Oral levetiracetam for prevention of busulfan-induced seizures in adult hematopoietic cell transplant.
Chaguaceda C; Aguilera-Jiménez V; Gutierrez G; Roura J; Riu G
Int J Clin Pharm; 2020 Apr; 42(2):351-354. PubMed ID: 32026356
[TBL] [Abstract][Full Text] [Related]
16. Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium.
Donnelly JP; Chen SC; Kauffman CA; Steinbach WJ; Baddley JW; Verweij PE; Clancy CJ; Wingard JR; Lockhart SR; Groll AH; Sorrell TC; Bassetti M; Akan H; Alexander BD; Andes D; Azoulay E; Bialek R; Bradsher RW; Bretagne S; Calandra T; Caliendo AM; Castagnola E; Cruciani M; Cuenca-Estrella M; Decker CF; Desai SR; Fisher B; Harrison T; Heussel CP; Jensen HE; Kibbler CC; Kontoyiannis DP; Kullberg BJ; Lagrou K; Lamoth F; Lehrnbecher T; Loeffler J; Lortholary O; Maertens J; Marchetti O; Marr KA; Masur H; Meis JF; Morrisey CO; Nucci M; Ostrosky-Zeichner L; Pagano L; Patterson TF; Perfect JR; Racil Z; Roilides E; Ruhnke M; Prokop CS; Shoham S; Slavin MA; Stevens DA; Thompson GR; Vazquez JA; Viscoli C; Walsh TJ; Warris A; Wheat LJ; White PL; Zaoutis TE; Pappas PG
Clin Infect Dis; 2020 Sep; 71(6):1367-1376. PubMed ID: 31802125
[TBL] [Abstract][Full Text] [Related]
17. Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors.
Styczyński J; Tridello G; Koster L; Iacobelli S; van Biezen A; van der Werf S; Mikulska M; Gil L; Cordonnier C; Ljungman P; Averbuch D; Cesaro S; de la Camara R; Baldomero H; Bader P; Basak G; Bonini C; Duarte R; Dufour C; Kuball J; Lankester A; Montoto S; Nagler A; Snowden JA; Kröger N; Mohty M; Gratwohl A;
Bone Marrow Transplant; 2020 Jan; 55(1):126-136. PubMed ID: 31455899
[TBL] [Abstract][Full Text] [Related]
18. Association of Antiepileptic Medications with Outcomes after Allogeneic Hematopoietic Cell Transplantation with Busulfan/Cyclophosphamide Conditioning.
McCune JS; Wang T; Bo-Subait K; Aljurf M; Beitinjaneh A; Bubalo J; Cahn JY; Cerny J; Chhabra S; Cumpston A; Dupuis LL; Lazarus HM; Marks DI; Maziarz RT; Norkin M; Prestidge T; Mineishi S; Krem MM; Pasquini M; Martin PJ
Biol Blood Marrow Transplant; 2019 Jul; 25(7):1424-1431. PubMed ID: 30871976
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
